Commonwealth Numbered Acts
[Index]
[Table]
[Search]
[Search this Act]
[Notes]
[Noteup]
[Previous]
[Download]
[Help]
COMMUNITY SERVICES AND HEALTH LEGISLATION AMENDMENT ACT 1989 No. 95 of 1989 - SCHEDULE
SCHEDULE
Section 18 NEW SCHEDULE 1A TO THE HEALTH INSURANCE ACT 1973
SCHEDULE 1A
PATHOLOGY SERVICES TABLE
RULES FOR INTERPRETATION OF THE PATHOLOGY SERVICES TABLE
1. In this Schedule:
"recognised pathologist" means a medical practitioner who, by reason of a
determination under section 61, is recognised for the purposes of this Act as
a specialist in the speciality of pathology.
2. Where an item includes the symbol "(SP)", the item relates to a pathology
service when rendered by or on behalf of an approved pathology practitioner
who is a recognised pathologist other than a pathology service:
(a) rendered pursuant to a request made in the course of the provision of
an out-patient service at a recognised hospital;
(b) rendered pursuant to a request made in respect of a person who was, at
the time when the request was made, a private patient in a recognised
hospital; or
(c) in the rendering of which:
(i) any pathology equipment of a recognised hospital, or a
laboratory included in a prescribed class of laboratories, is
used; or
(ii) any member of the staff of a recognised hospital, or a
laboratory included in a prescribed class of laboratories,
participates in the course of that member's employment with
that hospital or laboratory.
3. Where an item includes the symbol "(OP)", the item shall be taken to relate
to a pathology service other than a pathology service:
(a) to which an item that includes the symbol "(SP)" relates; or
(b) to which sub-section 16A (7) applies.
4. For the purposes of rules 2 and 3 each of the following classes of
laboratories is a prescribed class of laboratories:
(a) laboratories operated by the Commonwealth;
(b) laboratories operated by a State or an authority of a State;
(c) laboratories operated by the Northern Territory of Australia;
(d) laboratories operated by the Australian Capital Territory Community
and Health Service; and
(e) laboratories operated by an Australian tertiary institution.
5. Two or more pathology services rendered pursuant to 2 or more requests
shall be taken to have been rendered pursuant to a single request if:
(a) each pathology service is rendered to the same person;
(b) each pathology service is of a kind listed in the one item of the
table; and
(c) the determinations of the necessity for the pathology services were
made on the same day.
6. In rule 5, "service" includes an assay, estimation or test.
7. A reference in these rules to a request made to an approved pathology
practitioner includes a reference to a request that is deemed, for the
purposes of section 16A, to have been made to that approved pathology
practitioner.
8. Where:
(a) a pathology service (the 'first pathology service') is rendered
pursuant to a request;
(b) an item of the table applies to that pathology service;
(c) another pathology service (the 'second pathology service') is rendered
pursuant to the request; and
(d) the second pathology service is of a kind referred to in the item
referred to in paragraph (b);
the second pathology service shall be treated as if it were completely
subsumed within the first pathology service.
Example: Dr Proctor requests an extended blood grouping test (covered by item
1192) and the test includes a basic blood grouping test (covered by item
1187). Item 1187 is referred to in item 1192. Benefit is payable under item
1192 for the extended blood grouping test but benefit is not payable
separately under item 1187 for the basic blood grouping test.
9. For the purposes of Division 1-Haematology:
(a) if pathology services of a kind referred to in item 1187, 1188, 1192
or 1193 are rendered to a person during a period of hospitalisation,
the item applies only to the first pathology service of that kind
rendered to the person during that person's hospitalisation; and
(b) tests performed on material stored from a previous patient episode
(except tests specified in item 1198 or 1199) in response to a
subsequent request are treated as being part of that previous patient
episode if the second request is made within 14 days of that previous
patient episode. 10. For the purposes of Division 2-Chemical
Pathology:
(a) where a pathology service involving the measurement of any substance
in urine requires a 24 hour urine collection and/or calculation of a
substance/creatinine ratio, that pathology service is treated as
including any estimation of creatinine in other fluids necessary for
calculation; and
(b) tests performed on material stored from a previous patient episode in
response to a subsequent request are treated as being part of that
previous patient episode if the second request occurs within 14 days
of that previous patient episode. 11. For the purposes of Division
3-Microbiology:
(a) serial examinations or cultures means examinations or cultures
requested on the one occasion regardless of whether the materials are
received on different days by the approved pathology practitioner and
regardless of whether the examinations or cultures were requested on
one or more request forms by the treating practitioner; and
(b) tests performed on material which has been stored from a previous
patient episode in response to a subsequent request are treated as
being part of that previous patient episode if the further request
occurs within 14 days of that previous patient episode. 12. For the
purposes of Division 4-Immunology:
(a) tests performed on material which has been stored from a previous
patient episode in response to a subsequent request are treated as
being part of that previous patient episode if the further request
occurs within 14 days of that previous patient episode; and
(b) in items 2271, 2274, 2275, 2276, 2277, 2278, 2279 and 2280, the
estimation of a single antibody includes qualitative and quantitative
assays for that antibody. 13. For the purposes of Division
5-Histopathology:
(a) "biopsy material" means all tissue received by the approved pathology
practitioner from any operation or group of operations performed on a
patient at the one time other than a bone marrow biopsy; and
(b) where a pathology service relating to the examination of biopsy
material is rendered under an item set out in Division 5 in
circumstances where a further pathology service or pathology services
specified in an item or items in Division 5 are rendered also in
relation to that biopsy material, all those pathology services are
treated as one pathology service rendered under the one item
appropriate to the pathology services provided. 14. For the purposes
of Division 6-Cytopathology, "serial examinations" means examinations
requested on the one occasion regardless of whether the materials are
received on different days by the approved pathology practitioner and
regardless of whether the examinations were requested on one or more
request forms by the treating practitioner. 15. Where in these rules
provision is made for 2 or more pathology services to be treated as
one pathology service, a reference to an appropriate item is a
reference to the item which incorporates whichever of the symbols (SP)
or (OP) is relevant to the rendering of that pathology service. 16.
The lists of abbreviations at the end of the table are provided to
allow users of the table to identify and refer to particular pathology
services, or particular groups of pathology services, more accurately
and more conveniently.
------------------------------------------------------------------------------
-- Item
No. Pathology Service
Fees- All States
------------------------------------------------------------------------------
-- $ Division 1-Haematology
1163 Blood count consisting of erythrocyte count, C-reactive
protein, erythrocyte sedimentation rate, blood viscosity,
haemoglobin, platelet count, leucocyte count, reticulocyte
count-one or two procedures. SP 7.35 1164 Blood count consisting of
erythrocyte count, C-reactive
protein, erythrocyte sedimentation rate, blood viscosity,
haemoglobin, platelet count, leucocyte count, reticulocyte
count-one or two procedures. OP 5.55 1168 Three or more procedures to which
item 1163 applies, including
any calculation or measurement of erythrocyte or other indices.
SP 10.00 1169 Three of more procedures to which item 1164 applies, including
any calculation or measurement of erythrocyte or other indices.
OP 7.50 1170 Examination of blood film, with or without differential cell
count, or differential cell count with or without examination
of blood film, and the performance of any of these additional
services-Direct Coombs test, tests for heterophile antibodies,
cold agglutinins, examination of blood film by special stains
to demonstrate Heinz bodies, parasites or iron, or examination
of a blood film with alpha-naphthyl acetate esterase,
choloroacetate esterase, neutrophil alkaline phosphotase, nitro
blue tetrazolium, periodic acid Schiff, Sudan Black stains, or
Kleihauer test for HbF on blood film, including any services
specified in item 1419. SP 13.20 1171 Examination of blood film, with or
without differential cell
count, or differential cell count with or without examination
of blood film, and the performance of any of these additional
services-Direct Coombs test, tests for heterophile antibodies,
cold agglutinins, examination of blood film by special stains
to demonstrate Heinz bodies, parasites or iron, or examination
of a blood film with alpha-naphthyl acetate esterase,
choloroacetate esterase, neutrophil alkaline phosphotase, nitro
blue tetrazolium, periodic acid Schiff, Sudan Black stains, or
Kleihauer test for HbF on blood film, including any services
specified in item 1420. OP 9.90 1172 Full blood examination consisting of
items 1168 and 1170. SP 23.00 1173 Full blood examination consisting of items
1169 and 1171. OP 17.25 1176 Erythrocytes, qualitative or quantitative
assessment of
haemolysis or metabolic enzymes by-erythrocyte autohaemolysis
test, erythrocyte fragility test, sugar water test, erythrocyte
metabolic enzyme test, heat denaturation test, isopropanol
precipitation test, acid haemolysis test, and quantitation of
muramidase in serum or urine-one or more procedures. SP 30.50 1177
Erythrocytes, qualitative or quantitative assessment of
haemolysis or metabolic enzymes by-erythrocyte autohaemolysis
test, erythrocyte fragility test, sugar water test, erythrocyte
metabolic enzyme test, heat denaturation test, isopropanol
precipitation test, acid haemolysis test, and quantitation of
muramidase in serum or urine-one or more procedures. OP 22.90 1179 Tests for
the diagnosis of haemoglobinopathy consisting of
haemoglobin electrophoresis and two of the
following-examination for HbH, quantitation of HbA2 or HbF,
including any services specified in items 1163, 1168, 1170 and
1172. SP 47.50 1180 Tests for the diagnosis of haemoglobinopathy consisting of
haemoglobin electrophoresis and two of the
following-examination for HbH, quantitation of HbA2 or HbF,
including any services specified in items 1164, 1169, 1171 and
1173. OP 35.65 1181 Histopathological examination of sections of bone marrow
trephine biopsy including where indicated, examination of
marrow smears and any special stains and immuno-chemical
techniques, including any services specified in items 1163,
1168, 1170, 1172 and 1183. SP 146.00 1182 Histopathological examination of
sections of bone marrow
trephine biopsy including where indicated, examination of
marrow smears and any special stains and immuno-chemical
techniques, including any services specified in items 1164,
1169, 1171, 1173 and 1184. OP 109.50 1183 Bone marrow examination of aspirated
material including any
special stains, immuno-chemical techniques and clot sections
where necessary, including any services specified in items
1163, 1168, 1170 and 1172. SP 106.00 1184 Bone marrow examination of aspirated
material including any
special stains, immuno-chemical techniques and clot sections
where necessary, including any services specified in items
1164, 1169, 1171 and 1173. OP 79.50 1187 Blood grouping, including
back-grouping when performed-ABO and
Rh (D antigen). SP 12.80 1188 Blood grouping, including back-grouping when
performed-ABO and
Rh (D antigen). OP 9.60 1192 Blood grouping-Rh phenotypes, Kell system, Duffy
system, M and
N factors or any other blood group system-one or more systems,
including any services specified in item 1187. SP 25.50 1193 Blood grouping-Rh
phenotypes, Kell system, Duffy system, M and
N factors or any other blood group system-one of more systems,
including any services specified in item 1188. OP 19.15 1196 Blood grouping,
including back-grouping when performed, and
examination of serum for Rh and other blood group antibodies,
including identification and quantitative estimation of any
antibodies detected, and including any services specified in
items 1163, 1168, 1170 and 1172. SP 47.50 1197 Blood grouping, including
back-grouping when performed, and
examination of serum for Rh and other blood group antibodies,
including identification and quantitative estimation of any
antibodies detected, and including any services specified in
items 1164, 1169, 1171 and 1173. OP 35.65 1198 Compatibility testing,
including all necessary grouping checks
of patient and donor, examination for antibodies,
identification and, if necessary, quantitative estimation of
any antibodies detected and any services specified in items
1163, 1168, 1170, 1172, 1187 and 1196 including all testing
performed on any one day. SP 116.00 1199 Compatibility testing, including all
necessary grouping checks
of patient and donor, examination for antibodies,
identification and, if necessary, quantitative estimation of
any antibodies detected and any services specified in items
1164, 1169, 1171, 1173, 1188 and 1197 including all testing
performed on any one day. OP 87.00 1417 Examination of serum for blood group
antibodies including
identification and, if necessary, quantitative estimation of
any antibodies detected. SP 21.00 1418 Examination of serum for blood group
antibodies including
identification and, if necessary, quantitative estimation of
any antibodies detected. OP 15.75 1419 Direct Coombs test, qualitative or
quantitative test for cold
agglutinins, or heterophile antibodies, qualitative
spectroscopic examination of blood for abnormal haemoglobins,
qualitative test for red cell porphyrins and detection of
metalbumin (Schumm's test) excluding those services specified
in items 1170 and 1173-one or more tests. SP 11.60 1420 Direct Coombs test,
qualitative or quantitative test for cold
agglutinins, or heterophile antibodies, qualitative
spectroscopic examination of blood for abnormal haemoglobins,
qualitative test for red cell porphyrins and detection of
metalbumin (Schumm's test) excluding those services specified
in items 1171 and 1173-one or more tests. OP 8.70 1521 Skin bleeding time,
coagulation time, prothrombin time,
activated partial thromboplastin time, thrombin time (including
test for presence of an inhibitor and serial tests for
fibrinolysis), test for factor XIII deficiency, fibrinogen, or
one of-fibrinogen degradation products, fibrin monomer or
D-dimer-one estimation. SP 16.00 1522 Skin bleeding time, coagulation time,
prothrombin time,
activated partial thromboplastin time, thrombin time (including
test for presence of an inhibitor and serial tests for
fibrinolysis), test for factor XIII deficiency, fibrinogen, or
one of-fibrinogen degradation products, fibrin monomer or
D-dimer-one estimation. OP 12.00 1523 Two estimations specified in item 1521.
SP 21.00 1524 Two estimations specified in item 1522. OP 15.75 1525 Three
estimations specified in item 1521. SP 26.50 1526 Three estimations specified
in item 1522. OP 19.90 1527 Four or more estimations specified in item 1521.
SP 31.50 1528 Four or more estimations specified in item 1522. OP 23.65 1531
Quantitative assay, by one or more techniques, of plasminogen,
antithrombin III, Protein C, Protein S, heparin co-factor II,
Euglobulin clot lysis time and test for lupus anticoagulant-one
estimation. SP 31.50 1532 Quantitative assay, by one or more techniques, of
plasminogen,
antithrombin III, Protein C, Protein S, heparin co-factor II,
Euglobulin clot lysis time and test for lupus anticoagulant-one
estimation. OP 23.65 1533 Four or more estimations specified in item 1531. SP
100.00 1534 Four or more estimations specified in item 1532. OP 75.00 1535
Platelet aggregation in response to ADP, collagen, 5HT,
ristocetin or similar substance-one or more estimations. SP 63.00 1538
Platelet aggregation in response to ADP, collagen, 5HT,
ristocetin or similar substance-one or more estimations. OP 47.25 1539 Heparin
assay, only when monitoring a patient on subcutaneous
heparin or low molecular weight heparin-one or more
estimations. SP 42.00 1540 Heparin assay, only when monitoring a patient on
subcutaneous
heparin or low molecular weight heparin-one or more
estimations. OP 31.50 1541 Quantitative assay of Von Willebrand's factor
antigen (factor
VIII related antigen), Von Willebrand's factor (ristocetin
cofactor), factor II, factor V, factor VII, factor VIII, factor
IX, factor X, factor XI, factor XII, factor XIII, Fletcher
factor, Fitzgerald factor, Passovy factor-one estimation. SP 42.00 1542
Quantitative assay of Von Willebrand's factor antigen (factor
VIII related antigen), Von Willebrand's factor (ristocetin
cofactor), factor II, factor V, factor VII, factor VIII, factor
IX, factor X, factor XI, factor XII, factor XIII, Fletcher
factor, Fitzgerald factor, Passovy factor-one estimation. OP 31.50 1543 Two
estimations as specified in item 1541. SP 63.00 1544 Two estimations as
specified in item 1542. OP 47.25 1550 Three or more estimations as specified
in item 1541. SP 79.00 1551 Three or more estimations as specified in item
1542. OP 59.25 Division 2-Chemical pathology 1558 Quantitative estimation in
serum, plasma, urine or any other
body fluid, by any method except by reagent strip with or
without reflectance meter or electrophoresis of-alanine
amino-transferase, albumin, alkaline phosphatase, amylase,
aspartate aminotransferase, bicarbonate, bilirubin (total and
any fractions), calcium (total, dialysed or ionized), chloride,
cholesterol, creatine kinase, creatine kinase isoenzymes (when
not performed as specified in item 1734), creatinine,
fructosamine, gamma glutamyl transpeptidase, globulin, glucose,
lactate dehydrogenase, lipase, lithium, magnesium, phosphate,
potassium, total protein, sodium, triglycerides, urate,
urea-one estimation. SP 13.20 1559 Quantitative estimation in serum, plasma,
urine or any other
body fluid, by any method except by reagent strip with or
without reflectance meter or electrophoresis of-alanine
amino-transferase, albumin, alkaline phosphatase, amylase,
aspartate aminotransferase, bicarbonate, bilirubin (total and
any fractions), calcium (total, dialysed or ionized), chloride,
cholesterol, creatine kinase, creatine kinase isoenzymes (when
not performed as specified in item 1735), creatinine,
fructosamine, gamma glutamyl transpeptidase, globulin, glucose,
lactate dehydrogenase, lipase, lithium, magnesium, phosphate,
potassium, total protein, sodium, triglycerides, urate,
urea-one estimation. OP 9.90 1560 Two estimations specified in item 1558. SP
16.00 1561 Two estimations specified in item 1559. OP 12.00 1562 Three
estimations specified in item 1558. SP 18.60 1563 Three estimations specified
in item 1559. OP 13.95 1564 Four estimations specified in item 1558. SP 21.00
1565 Four estimations specified in item 1559. OP 15.75 1569 Five estimations
specified in item 1558. SP 23.50 1570 Five estimations specified in item 1559.
OP 17.65 1571 Six or more estimations specified in item 1558. SP 26.50 1572
Six or more estimations specified in item 1559. OP 19.90 1575 Qualitative
estimation by any method, except by reagent strip
or dip-stick of the following urine constituents-bilirubin,
cystine (cysteine), haemoglobin, melanin (melanogen),
myoglobin, porphobilinogen, porphyrins, urobilinogen or pH
measurement of body fluids other than urine (excepting urine
acidification test), or cryoglobulins or cryofibrinogen in
serum-one or more estimations. SP 12.60 1576 Qualitative estimation by any
method, except by reagent strip
or dip-stick of the following urine constituents-bilirubin,
cystine (cysteine), haemoglobin, melanin (melanogen),
myoglobin, porphobilinogen, porphyrins, urobilinogen or pH
measurement of body fluids other than urine (excepting urine
acidification test), or cryoglobulins or cryofibrinogen in
serum-one or more estimations. OP 9.45 1577 Qualitative estimation by any
method except by reagent strip or
dip-stick of the following faecal constituents-haemoglobin,
porphyrins, reducing substances-each estimation, to a maximum
of three estimations, taken on separate days. SP 8.40 1578 Qualitative
estimation by any method except by reagent strip or
dip-stick of the following faecal constituents-haemoglobin,
porphyrins, reducing substances-each estimation, to a maximum
of three estimations, taken on separate days. OP 6.30 1579 Immunological test
for human haemoglobin in faeces performed in
any twenty eight day period, including chemical test if
performed-one estimation-SP 16.00 1580 Immunological test for human
haemoglobin in faeces performed in
any twenty eight day period, including chemical test if
performed-one estimation. OP 12.00 1581 Two or more estimations specified in
item 1579. SP 36.50 1582 Two or more estimations specified in item 1580. OP
27.40 1583 Osmolality, estimation by osmometer, in serum or in urine-one
or more estimations. SP 31.50 1584 Osmolality, estimation by osmometer, in
serum or in urine-one
or more estimations. OP 23.65 1590 Quantitative estimation of blood gases
including tests
performed from-pO2, oxygen saturation, pCO2, bicarbonate, pH,
and any other measurement (eg. haemoglobin, potassium) or
calculation performed on the same specimen by the same
instrument or group of instruments-one or more estimation on
one specimen. SP. 43.00 1591 Quantitative estimation of blood gases including
tests
performed from-pO2, oxygen saturation, pCO2, bicarbonate, pH,
and any other measurement (eg. haemoglobin, potassium) or
calculation performed on the same specimen by the same
instrument or group of instruments-one or more estimation on
one specimen. OP. 32.25 1592 One or more estimations of blood gases as
specified in item
1590 on two or more specimens within any one day. SP 53.00 1593 One or more
estimations of blood gases as specified in item
1591 on two or more specimens within any one day. OP 39.75 1595 Calculus,
analysis of one or more. SP 39.00 1596 Calculus, analysis of one or more. OP
29.25 1598 Drug or chemical assays-including all qualitative and
quantitive tests on blood, urine or other body fluid for a drug
or drugs of abuse, including illegal drugs and legally
available drugs taken other than in appropriate dosage,
ingested or absorbed toxic chemicals including any services
specified in items 1712, 1714 and 1716, but excluding the
surveillance of sports people and athletes for performance
improving substances-one or more assays. SP 53.00 1599 Drug or chemical
assays-including all qualitative and
quantitive tests on blood, urine or other body fluid for a drug
or drugs of abuse, including illegal drugs and legally
available drugs taken other than in appropriate dosage,
ingested or absorbed toxic chemicals including any services
specified in items 1713, 1715 and 1717, but excluding the
surveillance of sports people and athletes for performance
improving substances-one or more assays. OP 39.75 1627 Drug assays-including
all qualitative and quantitive
estimations on blood, urine or other body fluid for a drug or
drugs of abuse or a therapeutic drug on a sample collected from
a patient participating in a drug abuse treatment programme, or
being treated for drug effects or under a court order or parole
board supervision, but excluding the detection of nicotine and
metabolites in smoking withdrawal programs-each assay to a
maximum of four assays within any twenty eight day period. SP 26.50 1628 Drug
assays-including all qualitative and quantitive
estimations on blood, urine or other body fluid for a drug or
drugs of abuse or a therapeutic drug on a sample collected from
a patient participating in a drug abuse treatment programme, or
being treated for drug effects or under a court order or parole
board supervision, but excluding the detection of nicotine and
metabolites in smoking withdrawal programs-each assay to a
maximum of four assays within any twenty eight day period. OP 19.90 1712 Drug
assay-quantitative estimation on blood or other body fluid
by any method or methods of a drug being used therapeutically
for the patient from whom the specimen was taken (excluding
antibiotics or antimicrobial chemotherapeutic agents)-one
estimation. SP 26.50 1713 Drug assay-quantitative estimation on blood or other
body fluid
by any method or methods of a drug being used therapeutically
for the patient from whom the specimen was taken (excluding
antibiotics or antimicrobial chemotherapeutic agents)-one
estimation. OP 19.90 1714 Two estimations specified in item 1712. SP 36.50
1715 Two estimations specified in item 1713. OP 27.40 1716 Three or more
estimations specified in item 1712. SP 47.50 1717 Three or more estimations
specified in item 1713. OP 35.65 1726 Amniotic fluid, spectrophotometric
examination of, estimation
of lecithin/sphingomyelin ratio or palmitic acid-one or more
examinations or estimations. SP 42.00 1727 Amniotic fluid, spectrophotometric
examination of, estimation
of lecithin/sphingomyelin ratio or palmitic acid-one or more
examinations or estimations. OP 31.50 1734 Electrophoresis, quantitative or
qualitative of serum, urine or
other body fluid to demonstrate protein classes or presence and
amount of paraprotein, or the isoenzymes of lactate
dehydrogenase, alkaline phosphatase and creatine kinase,
including the preliminary quantitation of total protein,
albumin and globulin or of total relevant enzyme activity, but
excluding lipoprotein electrophoresis-one examination. SP 39.00 1735
Electrophoresis, quantitative or qualitative of serum, urine or
other body fluid to demonstrate protein classes or presence and
amount of paraprotein, or the isoenzymes of lactate
dehydrogenase, alkaline phosphatase and creatine kinase,
including the preliminary quantitation of total protein,
albumin and globulin or of total relevant enzyme activity, but
excluding lipoprotein electrophoresis-one examination. OP 29.25 1736
Electrophoresis, quantitative or qualitative of concurrently
collected, or collected within a twenty eight day period, serum
and urine to demonstrate protein classes or presence and amount
of paraproteins, including the preliminary quantitation of
total protein, albumin and globulin, but excluding lipoprotein
electrophoresis-two or more examinations. SP 58.00 1737 Electrophoresis,
quantitative or qualitative of concurrently
collected, or collected within a twenty eight day period, serum
and urine to demonstrate protein classes or presence and amount
of paraproteins, including the preliminary quantitation of
total protein, albumin and globulin, but excluding lipoprotein
electrophoresis-two or more examinations. OP 43.50 1738 Alpha-feto protein,
Alpha-1 antitrypsin, Alpha-2 macroglobulin,
beta-2 microglobulin, C-1 esterase inhibitor, Caeruloplasmin,
Ferritin (unless specified in item 1752), Haptoglobins,
Microalbumin (in proven diabetes mellitus), Transferrin (unless
specified in item 1752) and, in the follow up of proven
malignancy, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen,
Carcinoembryonic antigen, Prostatic Acid Phosphatase (one or
more fractions), Prostate specific antigen-quantitative
estimation in serum, urine or other body fluid-one estimation.
SP 25.50 1739 Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin,
beta-2 microglobulin, C-1 esterase inhibitor, Caeruloplasmin,
Ferritin (unless specified in item 1753), Haptoglobins,
Microalbumin (in proven diabetes mellitus), Transferrin (unless
specified in item 1753) and, in the follow up of proven
malignancy, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen,
Carcinoembryonic antigen, Prostatic Acid Phosphatase (one or
more fractions), Prostate specific antigen-quantitative
estimation in serum, urine or other body fluid-one estimation.
OP 19.15 1740 Two or more estimations specified in item 1738. SP 47.50 1741
Two or more estimations specified in item 1739. OP 35.65 1752 Iron studies
consisting of quantitative analysis of iron,
transferrin or iron binding capacity and ferritin. SP 50.00 1753 Iron studies
consisting of quantitative analysis of iron,
transferrin or iron binding capacity and ferritin. OP 37.50 1768 Serum B12,
serum folate-one or more estimations within any
twenty eight day period. SP 31.50 1769 Serum B12, serum folate-one or more
estimations within any
twenty eight day period. OP 23.65 1770 Red cell folate and serum B12 and, if
required, serum folate,
to a maximum of three estimations in any twelve month period.
SP 57.50 1771 Red cell folate and serum B12 and, if required, serum folate,
to a maximum of three estimations in any twelve month period.
OP 43.00 1780 Vitamins, quantitative estimation in blood, urine or other body
fluid, by direct or indirect means, of Vitamins A, B1, B2, B3,
B6, C, and E-one or more estimations within any six month
period. SP 39.00 1783 Vitamins, quantitative estimation in blood, urine or
other body
fluid, by direct or indirect means, of Vitamins A, B1, B2, B3,
B6, C, and E-one or more estimations within any six month
period. OP 29.25 1786 Vitamin D or D fractions-one or more estimations. SP
39.00 1787 Vitamin D or D fractions-one or more estimations. OP 29.25 1791
Alcohol, ammonia, angiotensin converting enzyme, neonatal
bilirubin (one or more fractions), cholinesterase, cystine
(cysteine) , hydroxyindoleacetic acid, hydroxyproline, lactate,
pyruvate, oxalate, xylose, zinc-one quantitative estimation. SP 31.50 1792
Alcohol, ammonia, angiotensin converting enzyme, neonatal
bilirubin (one or more fractions), cholinesterase, cystine
(cysteine) , hydroxyindoleacetic acid, hydroxyproline, lactate,
pyruvate, oxalate, xylose, zinc-one quantitative estimation. OP 23.65 1795 Two
or more estimations specified in item 1791. SP 49.50 1798 Two or more
estimations specified in item 1792. OP 37.15 1871 Aluminium, arsenic,
beryllium, cadmium, copper, chromium, gold,
manganese, mercury, nickel, selenium, strontium-in blood, urine
or other body fluid or tissue-one or more estimations within
any six month period. SP 44.50 1872 Aluminium, arsenic, beryllium, cadmium,
copper, chromium, gold,
manganese, mercury, nickel, selenium, strontium-in blood, urine
or other body fluid or tissue-one or more estimations within
any six month period. OP 33.40 1895 Blood lead estimation, other than for
occupational health
screening purposes, to a maximum of three estimations in any
six month period-each estimation. SP 39.00 1896 Blood lead estimation, other
than for occupational health
screening purposes, to a maximum of three estimations in any
six month period-each estimation. OP 29.25 1959 Porphyrins (one or more
fractions), Catecholamines (one or more
fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic
Acid (HVA), Methoxy Hydroxy Phenylethylene Glycol (MHPG),
Phenyl Acetic Acid (PAA)-quantitative including any qualitative
estimations-one or more estimations. SP 51.00 1960 Porphyrins (one or more
fractions), Catecholamines (one or more
fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic
Acid (HVA), Methoxy Hydroxy Phenylethylene Glycol (MHPG),
Phenyl Acetic Acid (PAA)-quantitative including any qualitative
estimations-one or more estimations. OP 38.25 1963 Faecal fat-one or more
quantitative estimations within any
twenty eight day period. SP 51.00 1964 Faecal fat-one or more quantitative
estimations within any
twenty eight day period. OP 38.25 1969 Solid tissue or tissues excluding blood
elements-assay of one
or two enzymes. SP 51.00 1970 Solid tissue or tissues excluding blood
elements-assay of one
or two enzymes. OP 38.25 1975 Assay of three to five enzymes as specified in
item 1969. SP 95.00 1976 Assay of three to five enzymes as specified in item
1970. OP 71.25 1977 Assay of six or more enzymes as specified in item 1969. SP
126.00 1978 Assay of six or more enzymes as specified in item 1970. OP 94.50
1983 Thyroid function tests, including thyrotrophin (TSH) and at
least one or more of the following tests-free thyroxine index,
free thyroxine, free T3, total T3, thyroxine binding globulin.
SP 53.00 1984 Thyroid function tests, including thyrotrophin (TSH) and at
least one or more of the following tests-free thyroxine index,
free thyroxine, free T3, total T3, thyroxine binding globulin.
OP 39.75 1985 Thyrotrophin releasing hormone (TRH) test, including provision
and administration of TRH and all necessary estimations of
hormones. SP 63.00 1986 Thyrotrophin releasing hormone (TRH) test, including
provision
and administration of TRH and all necessary estimations of
hormones. OP 47.25 2021 Hormones and hormone binding proteins, quantitative
estimation
by any method of-ACTH, Aldosterone, Androstenedione, C-peptide,
Calcitonin, Cortisol, Cyclic AMP, DHEAS, FSH, Gastrin, Growth
hormone, Hydroxyprogesterone, Insulin, LH, Oestradiol,
Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex
hormone binding globulin, Somatomedin C(IgF1), free or total
Testosterone, Urine steroid fraction or fractions, Vasoactive
intestinal peptide, Vasopressin (anti diuretic hormone)-one
estimation. SP 36.50 2024 Hormones and hormone binding proteins, quantitative
estimation
by any method of-ACTH, Aldosterone, Androstenedione, C-peptide,
Calcitonin, Cortisol, Cyclic AMP, DHEAS, FSH, Gastrin, Growth
hormone, Hydroxyprogesterone, Insulin, LH, Oestradiol,
Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex
hormone binding globulin, Somatomedin C(IgF1), free or total
Testosterone, Urine steroid fraction or fractions, Vasoactive
intestinal peptide, Vasopressin (anti diuretic hormone)-one
estimation. OP 27.40 2025 Two estimations specified in item 2021. SP 58.00
2026 Two estimations specified in item 2024. OP 43.50 2027 Three estimations
specified in item 2021. SP 73.00 2028 Three estimations specified in item
2024. OP 54.75 2029 Four estimations specified in item 2021. SP 89.00 2030
Four estimations specified in item 2024. OP 66.75 2031 Five estimations
specified in item 2021. SP 100.00 2032 Five estimations specified in item
2024. OP 53.45 2033 Six or more estimations specified in item 2021. SP 112.00
2034 Six or more estimations specified in item 2024. OP 84.00 2037 Hormone
receptor assay on proven primary breast carcinoma or
subsequent lesion in the breast or metastasis from a breast
carcinoma-one or more assays. SP 102.00 2038 Hormone receptor assay on proven
primary breast carcinoma or
subsequent lesion in the breast or metastasis from a breast
carcinoma-one or more assays. OP 76.50 2039 HDL cholesterol, estimation of, in
patients, with serum
cholesterol >5.5mmol/1-each estimation to a maximum of four
estimations in any twelve month period. SP 16.00 2040 HDL cholesterol,
estimation of, in patients, with serum
cholesterol >5.5mmol/1-each estimation to a maximum of four
estimations in any twelve month period. OP 12.00 2043 Glycosylated haemoglobin
only when performed in the management
of established diabetes-each estimation to a maximum of four
estimations in any twelve month period. SP 21.50 2044 Glycosylated haemoglobin
only when performed in the management
of established diabetes-each estimation to a maximum of four
estimations in any twelve month period. OP 16.15 Division 3-Microbiology 2083
Microscopic examination including serial examinations of
material other than blood, from one or more sites, obtained
directly from a patient and excluding material from
cultures-wet film, including differential cell count if
performed, examination for dermatophytes or dark ground
illumination, of stained preparation or preparations using any
relevant stain or stains-one or more examinations. SP 9.50 2084 Microscopic
examination including serial examinations of
material other than blood, from one or more sites, obtained
directly from a patient and excluding material from
cultures-wet film, including differential cell count if
performed, examination for dermatophytes or dark ground
illumination, or stained preparation or preparation using any
relevant stain or stains-one or more examinations. OP 7.15 2085 Microscopic
examination of faeces for parasites using
concentration techniques including the use of appropriate
stains, to a maximum of three estimations taken on separate
days including any services specified in item 2083-each
estimation. SP 16.00 2086 Microscopic examination of faeces for parasites
using
concentration techniques including the use of appropriate
stains, to a maximum of three estimations taken on separate
days including any services specified in item 2084-each
estimation. OP 12.00 2087 The cultural examination and miscroscopical
examination when
indicated (including the detection of antigens not elsewhere
specified in the Schedule) to determine the presence of
pathogenic micro-organisms, including fungi but excluding
viruses, from nasal swabs, throat swabs, eye swabs and ear
swabs, including pathogen identification and antibiotic
sensitivity testing, including any services specified in item
2083, 2089 and 2098-one or more sites. SP 25.00 2088 The cultural examination
and miscroscopical examination when
indicated (including the detection of antigens not elsewhere
specified in the Schedule) to determine the presence of
pathogenic micro-organisms, including fungi but excluding
viruses, from nasal swabs, throat swabs, eye swabs and ear
swabs, including pathogen identification and antibiotic
sensitivity testing, including any services specified in item
2084, 2090 and 2099-one or more sites. OP 18.75 2089 Microscopical and
cultural examination (including the detection
of antigens not elsewhere specified in the Schedule) to
determine the presence of pathogenic micro-organisms, including
fungi but excluding viruses, from the following sites-skin or
other superficial sites, urethral, vaginal, cervical, sputum
(except when part of item 2119) and rectal (except for faecal
pathogens), including pathogenic identification and antibiotic
sensitivity testing, including any services specified in item
2083, 2087 and 2098-one or more sites. SP 36.50 2090 Microscopical and
cultural examination (including the detection
of antigens not elsewhere specified in the Schedule) to
determine the presence of pathogenic micro-organisms, including
fungi but excluding viruses, from the following sites-skin or
other superficial sites, urethral, vaginal, cervical, sputum
(except when part of item 2120) and rectal (except for faecal
pathogens), including pathogenic identification and antibiotic
sensitivity testing, including any services specified in item
2084, 2088 and 2099-one or more sites. OP 27.40 2098 Microscopical and
cultural examination (including the detection
of antigens not elsewhere specified in the Schedule) of
post-operative wounds, aspirations of body cavities, synovial
fluid CSF and operative or biopsy specimens for the presence of
pathogenic micro-organisms, including fungi but excluding
viruses, involving aerobic and anaerobic culture and the use of
different culture media and including pathogen identification
and antibiotic sensitivity testing, including any services
specified in item 2083, 2087 and 2089-one or more sites. SP 49.50 2099
Microscopical and cultural examination (including the detection
of antigens not elsewhere specified in the Schedule) of
post-operative wounds, aspirations of body cavities, synovial
fluid CSF and operative or biopsy specimens for the presence of
pathogenic micro-organisms, including fungi but excluding
viruses, involving aerobic and anaerobic culture and the use of
different culture media and including pathogen identification
and antibiotic sensitivity testing, including any services
specified in item 2084, 2088 and 2090-one or more sites. OP 37.15 2117
Cultural examination (including the detection of antigens not
elsewhere specified in the Schedule) of faeces to determine the
presence or absence of faecal pathogens, involving the use of
at least two selective or enrichment media as well as culture
in at least two different atmospheres and includes pathogen
identification and antibiotic sensitivity testing, including
any services specified in item 2083, to a maximum of three
specimens in any seven day period-each examination. SP 60.00 2118 Cultural
examination (including the detection of antigens not
elsewhere specified in the Schedule) of faeces to determine the
presence or absence of faecal pathogens, involving the use of
at least two selective or enrichment media as well as culture
in at least two different atmospheres and includes pathogen
identification and antibiotic sensitivity testing, including
any services specified in item 2084, to a maximum of three
specimens in any seven day period-each examination. OP 45.00 2119 Microscopy
with appropriate stains and cultural examinations of
three specimens of sputum, urine or other bodily fluids for
mycobacteria and any other bacterial pathogens, including
pathogen identification and antibiotic sensitivity testing and
including any services specified in item 2083. SP 84.00 2120 Microscopy with
appropriate stains and cultural examinations of
three specimens of sputum, urine or other bodily fluids for
mycobacteria and any other bacterial pathogens, including
pathogen identification and antibiotic sensitivity testing and
including any services specified in item 2084. OP 63.00 2123 Blood culture to
determine the presence or absence of
pathogenic micro-organisms excluding viruses, including serial
cultures and sub-cultures, any relevant cultural methods and
any tests necessary to identify any cultured pathogen and
necessary antibiotic sensitivity testing-each set of cultures
to a maximum of three sets. SP 22.00 2124 Blood culture to determine the
presence or absence of
pathogenic micro-organisms excluding viruses, including serial
cultures and sub-cultures, any relevant cultural methods and
any tests necessary to identify any cultured pathogen and
necessary antibiotic sensitivity testing-each set of cultures
to a maximum of three sets. OP 16.50 2127 Urine examination including serial
examination, with cell
count, relevant stained preparations, culture, colony count by
any method, identification of any cultured pathogens,
antibiotic sensitivity testing when necessary, and with any
relevant general examination for pH, specific gravity, blood,
albumin, urobilinogen, sugar, acetone or bile salts. (Simple
culture by dip slide is excluded from this item). SP 26.50 2128 Urine
examination including serial examination, with cell
count, relevant stained preparations, culture, colony count by
any method, identification of any cultured pathogens,
antibiotic sensitivity testing when necessary, and with any
relevant general examination for pH, specific gravity, blood,
albumin, urobilinogen, sugar, acetone or bile salts. (Simple
culture by dip slide is excluded from this item). OP 19.90 2129 Direct
detection of the antigens of Haemophilus influenzae,
Streptococcus pneumoniae, Neisseria meningitidis, Group B
streptococcus (in CSF and urine specimens only), RSV,
cryptococcal antigens and Varicella Zoster-one or more
estimations. SP 21.00 2130 Direct detection of the antigens of Haemophilus
influenzae,
Streptococcus pneumoniae, Neisseria meningitidis, Group B
streptococcus (in CSF and urine specimens only), RSV,
cryptococcal antigens and Varicella Zoster-one or more
estimations. OP 15.75 2133 Direct detection of Chlamydia from clinical
material, not
cultures-one or more estimations. SP 12.60 2134 Direct detection of Chlamydia
from clinical material, not
cultures-one or more estimations. OP 9.45 2135 Direct detection of Herpes
simplex from clinical material, not
cultures-one or more estimations. SP 12.60 2136 Direct detection of Herpes
simplex from clinical material, not
cultures-one or more estimations. OP 9.45 2139 Investigation for Herpes
simplex virus (one or more types) or
Chlamydia trachomatis, in material obtained directly from a
patient, by one or more cultural methods, including any
services specified in items 2133 and 2135. SP 36.50 2140 Investigation for
Herpes simplex virus (one or more types) or
Chlamydia trachomatis, in material obtained directly from a
patient, by one or more cultural methods, including any
services specified in items 2134 and 2136. OP 27.40 2145 Serology including
IgG and IgM estimations of Rubella,
toxoplasma or CMV when performed during pregnancy-one or more
assays. SP 17.80 2146 Serology including IgG and IgM estimations of Rubella,
toxoplasma or CMV when performed during pregnancy-one or more
assays. OP 13.35 2181 Antibodies to microbial or exogenous antigens not
elsewhere
specified in the Schedule-estimation of one antibody. SP 17.80 2182 Antibodies
to microbial or exogenous antigens not elsewhere
specified in the Schedule-estimation of one antibody. OP 13.35 2183 Two
estimations specified in item 2181. SP 27.50 2184 Two estimations specified in
item 2182. OP 20.65 2185 Three estimations specified in item 2181. SP 36.50
2186 Three estimations specified in item 2182. OP 27.40 2187 Four estimations
specified in item 2181. SP 46.00 2188 Four estimations specified in item 2182.
OP 34.50 2189 Five estimations specified in item 2181. SP 56.00 2190 Five
estimations specified in item 2182. OP 42.00 2191 Six or more estimations
specified in item 2181. SP 65.00 2192 Six or more estimations specified in
item 2182. OP 48.75 2221 Hepatitis B surface antigen test. SP 17.80 2222
Hepatitis B surface antigen test. OP 13.35 2223 Hepatitis B serology to define
the immune status of an
individual, including at least Hepatitis B surface antibody or
Hepatitis B core antibody tests, including services specified
in items 2221, 2229 and 2231. SP 24.00 2224 Hepatitis B serology to define the
immune status of an
individual, including at least Hepatitis B surface antibody or
Hepatitis B core antibody tests, including services specified
in items 2222, 2230 and 2232. OP 18.00 2229 All serological tests performed
for the identification of the
agent causing acute hepatitis, which must include Hepatitis B
surface antigen, Hepatitis B core IgM antibody and Hepatitis A
IgM antibody tests and those services specified in items 2221,
2223 and 2232. SP 47.50 2230 All serological tests performed for the
identification of the
agent causing acute hepatitis, which must include Hepatitis B
surface antigen, Hepatitis B core IgM antibody and Hepatitis A
IgM antibody tests and those services specified in items 2222,
2224 and 2232. OP 35.65 2231 All tests performed in the follow up of a patient
with proven
Hepatitis B, including Hepatitis B surface antigen and either
Hepatitis Be antigen or Hepatitis B surface antibody tests,
including services specified in items 2221 and 2223. SP 34.50 2232 All tests
performed in the follow up of a patient with proven
Hepatitis B, including Hepatitis B surface antigen and either
Hepatitis Be antigen or Hepatitis B surface antibody tests,
including services specified in items 2222 and 2224. OP 25.90 2235 Antibiotics
or anti-microbial chemo-therapeutic agents,
concentration in serum, urine or other body fluid, by direct
quantitative measurement of the agent-one or more estimations.
SP 31.50 2236 Antibiotics or anti-microbial chemo-therapeutic agents,
concentration in serum, urine or other body fluid, by direct
quantitative measurement of the agent-one or more estimations.
OP 23.65 Division 4-Immunology 2239 Examination for, and identification of, a
paraprotein (not
previously identified), the presence of which is suggested by
other tests (eg item 1734, 1736 or 2245), on serum, urine or
other body fluid, or examination of CSF for oligoclonal
proteins by immunoelectrophoresisor immunofixation-one or more
procedures. SP 39.00 2240 Examination for, and identification of, a
paraprotein (not
previously identified), the presence of which is suggested by
other tests (eg item 1735, 1737 or 2246), on serum, urine or
other body fluid, or examination of CSF for oligoclonal
proteins by immunoelectrophoresisor immunofixation-one or more
procedures. OP 29.25 2241 Examination for, and identification of, a
paraprotein (not
previously identified), the presence of which is suggested by
other tests (eg item 1734, 1736 or 2245), on serum and urine
concurrently collected-two or more procedures. SP 58.00 2242 Examination for,
and identification of, a paraprotein (not
previously identified), the presence of which is suggested by
other tests (eg item 1735, 1737 or 2246), on serum and urine
concurrently collected-two or more procedures. OP 43.50 2245 Immunoglobulins
G, A, M or D, quantitative estimation in serum,
urine or other body fluid, by any method-estimation of one
immunoglobin. SP 19.00 2246 Immunoglobulins G, A, M or D, quantitative
estimation in serum,
urine or other body fluid, by any method-estimation of one
immunoglobin. OP 14.25 2251 Two estimations specified in item 2245. SP 29.50
2252 Two estimations specified in item 2246. OP 22.15 2253 Three or more
estimations specified in item 2245. SP 40.00 2254 Three or more estimations
specified in item 2246. OP 30.00 2255 Subclasses of Immunoglobulin G, 1 to 4,
estimation where there
is a reduced level of clinical significance of either total IgG
or IgA-one or more estimations. SP 58.00 2256 Subclasses of Immunoglobulin G,
1 to 4, estimation where there
is a reduced level of clinical significance of either total IgG
or IgA-one or more estimations. OP 43.50 2257 Immunoglobulin E (total),
quantitative estimation by any method
or methods, with a maximum of two estimations in any twelve
month period. SP 33.50 2258 Immunoglobulin E (total), quantitative estimation
by any method
or methods, with a maximum of two estimations in any twelve
month period. OP 25.19 2259 Specific IgG or IgE antibodies to potential
allergens-one or
more tests for single or multiple allergens with a maximum of
four estimations in any twelve month period. SP 30.50 2260 Specific IgG or IgE
antibodies to potential allergens-one or
more tests for single or multiple allergens with a maximum of
four estimations in any twelve month period. OP 22.90 2261 Antinuclear
antibodies, detection in serum or other body
fluids. SP 31.50 2262 Antinuclear antibodies, detection in serum or other body
fluids. OP 23.65 2263 Quantitation of antinuclear antibodies and measurement
of DNA
binding (by Farr assay), performed only where a positive titre
greater than 1 in 10 is obtained including services specified
in item 2261. SP 70.00 2266 Quantitation of antinuclear antibodies and
measurement of DNA
binding (by Farr assay), performed only where a positive titre
greater than 1 in 10 is obtained including services specified
in item 2262. OP 52.50 2267 Antibodies to extractable nuclear antigens,
detection of in
serum or other body fluids. SP 26.50 2268 Antibodies to extractable nuclear
antigens, detection of in
serum or other body fluids. OP 19.90 2269 Characterization of antibodies to
extractable nuclear antigens,
performed only where a positive result is obtained including
services specified in item 2267. SP 42.00 2270 Characterization of antibodies
to extractable nuclear antigens,
performed only where a positive result is obtained including
services specified in item 2268. OP 31.50 2271 Antibodies to tissue antigens
which are not elsewhere specified
in an item in the Schedule-estimation of one antibody. SP 31.50 2274
Antibodies to tissue antigens which are not elsewhere specified
in an item in the Schedule-estimation of one antibody. OP 23.65 2275 Two
estimations specified in item 2271. SP 36.50 2276 Two estimations specified in
item 2274. OP 27.40 2277 Three estimations specified in item 2271. SP 42.00
2278 Three estimations specified in item 2274. OP 31.50 2279 Four or more
estimations specified in item 2271. SP 47.50 2280 Four or more estimations
specified in item 2274. OP 35.65 2281 Rheumatoid factor, detection of by any
technique. SP 12.60 2282 Rheumatoid factor, detection of by any technique. OP
9.45 2283 Quantitation of Rheumatoid factor where detected, including
services specified in item 2281. SP 25.00 2284 Quantitation of Rheumatoid
factor where detected, including
services specified in item 2282. OP 18.75 2289 Complement-total and
components-one quantitative estimation. SP 21.00 2290 Complement-total and
components-one quantitative estimation. OP 15.75 2291 Two estimations as
specified in item 2289. SP 31.50 2292 Two estimations as specified in item
2290. OP 23.65 2293 Three or more estimations as specified in item 2289. SP
42.00 2312 Three or more estimations as specified in item 2290. OP 31.50 2313
Leucocyte fractionation as a preliminary to leucocyte marker or
leucocyte function tests. SP 39.00 2314 Leucocyte fractionation as a
preliminary to leucocyte marker or
leucocyte function tests. OP 29.25 2315 Functional tests for leucocytes,
including use of all
appropriate techniques (except E. rosette technique or similar
and any test specified in the HAEMATOLOGY DIVISION of the
Schedule). SP 66.00 2316 Functional tests for leucocytes, including use of all
appropriate techniques (except E. rosette technique or similar
and any test specified in the HAEMATOLOGY DIVISION of the
Schedule). OP 49.50 2317 Leucocyte surface marker characterization by
immunofluorescence
or immunoenzyme techniques to assess lymphoid populations using
a minimum of three monoclonal antibodies, including any
services in item 2319-one or more estimations. SP 84.00 2318 Leucocyte surface
marker characterization by immunofluorescence
or immunoenzyme techniques to assess lymphoid populations using
a minimum of three monoclonal antibodies, including any
services in item 2320-one or more estimations. OP 63.00 2319 Leucocyte surface
marker characterization by immunofluorescence
or immunoenzyme techniques in the investigation of a probable
haematological malignancy using, a minimum of seven monoclonal
antibodies, including any services in item 2317-one or more
estimations. SP 200.00 2320 Leucocyte surface marker characterization by
immunofluorescence
or immunoenzyme techniques in the investigation of a probable
haematological malignancy using, a minimum of seven monoclonal
antibodies, including any services in item 2318-one or more
estimations. OP 150.00 2321 HLA typing comprising A, B, C and DR phenotypes.
SP 89.00 2322 HLA typing comprising A, B, C and DR phenotypes. OP 66.75 2323
HLA typing, excluding any services specified in item 2321-one
or more antigens. SP 36.50 2324 HLA typing, excluding any services specified
in item 2322-one
or more antigens. OP 27.40 2325 Mantoux test. SP 12.60 2326 Mantoux test. OP
9.45 Division 5-Histopathology 2327 Histopathology examination of biopsy
material including all
tissue processing, staining and professional opinion or
opinions. SP 89.00 2328 Histopathology examination of biopsy material
including all
tissue processing, staining and professional opinion or
opinions. OP 66.75 2329 Immediate frozen section diagnosis of biopsy material,
including any other histopathology examination. SP 166.00 2330 Immediate
frozen section diagnosis of biopsy material,
including any other histopathology examination. OP 124.50 2331
Immunohistochemical investigation of biopsy material by one or
more of immunofluorescent, immunoperoxidase or other labelled
antibody techniques including any other histopathology
examination. SP 126.00 2332 Immunohistochemical investigation of biopsy
material by one or
more of immunofluorescent, immunoperoxidase or other labelled
antibody techniques including any other histopathology
examination. OP 94.50 2333 Electron microscopy of biopsy material including
any other
histopathology examination. SP. 134.00 2337 Electron microscopy of biopsy
material including any other
histopathology examination. OP. 100.50 Division 6-Cytopathology 2338
Cytological examination of smears from cervix or vagina for
detection of pre-cancerous or cancerous changes-one or more
examinations. SP 19.40 2339 Cytological examination of smears from cervix or
vagina for
detection of pre-cancerous or cancerous changes-one or more
examinations. OP 14.55 2340 Cytological examination including serial
examinations of smears
from skin, nipple discharge, lip, mouth, nose or anus for
detection of pre-cancerous or cancerous changes-one or more
examinations. SP 19.40 2341 Cytological examination including serial
examinations of smears
from skin, nipple discharge, lip, mouth, nose or anus for
detection of pre-cancerous or cancerous changes-one or more
examinations. OP 14.55 2343 Cytological examination including serial
examinations for
malignant cells of body fluids, sputum (single specimen),
urine, washings or brushings not specified in item 2340 and any
histopathological service performed-one or more examinations.
SP 38.00 2344 Cytological examination including serial examinations for
malignant cells of body fluids, sputum (single specimen),
urine, washings or brushings not specified in item 2341 and any
histopathological service performed-one or more examinations.
OP 28.50 2348 Cytological examination including examination of a series of
three sputum or urine specimens for malignant cells. SP 79.00 2349 Cytological
examination including examination of a series of
three sputum or urine specimens for malignant cells. OP 59.25 2350 Cytological
examination of material obtained from a patient by
fine needle aspiration of solid tissue or tissues. SP 47.50 2351 Cytological
examination of material obtained from a patient by
fine needle aspiration of solid tissue or tissues. OP 35.65 2355 Cytological
examination of material obtained from a patient by
fine needle aspiration of solid tissue or tissues where the
aspiration is performed by a recognised pathologist, or where a
recognised pathologist attends the aspiration and performs
cytological examination during the attendance. SP 89.00 2356 Cytological
examination of material obtained from a patient by
fine needle aspiration of solid tissue or tissues where the
aspiration is performed by a recognised pathologist, or where a
recognised pathologist attends the aspiration and performs
cytological examination during the attendance. OP 66.75 Division
7-Cytogenetics 2360 Chromosome studies, including preparation, count and
karyotyping of one or more of amniotic fluid, bone marrow, skin
and any other tissue or fluid excluding blood-one or more
estimations. SP 172.00 2361 Chromosome studies, including preparation, count
and
karyotyping of one or more of amniotic fluid, bone marrow, skin
and any other tissue or fluid excluding blood-one or more
estimations. OP 129.00 2363 Chromosome studies, including preparation, count
and
karyotyping of blood. SP 156.00 2364 Chromosome studies, including
preparation, count and
karyotyping of blood. OP 117.00 2365 Chromosome indentification by banding
techniques (using
fluorescein, Giemsa, or centromere staining of high resolution
analysis); or by fragile X-site determination-one or more
identifications. SP 134.00 2366 Chromosome indentification by banding
techniques (using
fluorescein, Giemsa, or centromere staining of high resolution
analysis); or by fragile X-site determination-one or more
identifications. OP 100.50 Division 8-Infertility and pregnancy tests 2370
Semen examination for presence of spermatozoa or examination of
cervical mucus for spermatozoa (Huhner's test). SP 8.80 2371 Semen examination
for presence for spermatozoa or examination
of cervical mucus for spermatozoa (Huhner's test). OP 6.60 2372 Semen
examination, involving measurement of volume, sperm
count, motility, examination of stained preparations,
morphology, and, if performed, differential count and one or
more chemical tests, with a maximum of four examinations in any
twelve month period. SP 36.50 2373 Semen examination, involving measurement of
volume, sperm
count, motility, examination of stained preparations,
morphology, and, if performed, differential count and one or
more chemical tests, with a maximum of four examinations in any
twelve month period. OP 27.40 2377 Sperm antibodies, sperm penetrating
ability-one or more tests.
SP 23.50 2378 Sperm antibodies, sperm penetrating ability-one or more tests.
OP 17.65 2379 Chorionic gonadotrophin (beta-HCG), qualitative estimation in
serum or urine by one or more methods, including serial
dilution if performed, for diagnosis of pregnancy-one or more
estimations. SP 12.80 2380 Chorionic gonadotrophin (beta-HCG), qualitative
estimation in
serum or urine by one or more methods, including serial
dilution if performed, for diagnosis of pregnancy-one or more
estimations. OP 9.60 2384 Chorionic gonadotrophin (beta-HCG), qualitative (if
performed)
and quantitative estimation in serum by one or more methods for
diagnosis of hydatidiform mole, HCG-secreting neoplasm,
threatened abortion or follow-up of abortion. SP 36.50 2385 Chorionic
gonadotrophin (beta-HCG), qualitative (if performed)
and quantitative estimation in serum by one or more methods for
diagnosis of hydatidiform mole, HCG-secreting neoplasm,
threatened abortion or follow-up of abortion. OP 27.40 Division 9-Simple basic
pathology tests 2389 Blood count consisting of leucocyte count, erythrocyte
sedimentation rate, examination of blood film (including
differential leucocyte count) or any or all of haemoglobin
estimation, haematocrit estimation or erythrocyte count-one
procedure. 3.90 2390 Two procedures specified in item 2389 5.85 2391 Three or
more procedures specified in item 2389 7.80 2393 Microscopical examination of
urine. 3.90 2394 Pregnancy test by one or more immunochemical methods. 9.60
2395 Microscopical examination of wet film other than urine. 5.85 1396
Microscopical examination of gram stained film. 7.40 1397 Chemical tests for
occult blood in faeces by reagent stick,
strip, tablet or similar method. 1.95 2398 Microscopical examination screening
for fungi in skin, hair or
nails-one or more sites. 5.85 2399 Mantoux test. 9.60 2400 Seminal examination
for presence of spermatozoa. 5.85
------------------------------------------------------------------------------
-- LISTS OF ABBREVIATIONS
A. ABBREVIATIONS FOR GROUPS OF TESTS
------------------------------------------------------------------------------
-- Group Estimations
Included in Group Abbreviation Item
Numbers
------------------------------------------------------------------------------
-- Cardiac Enzymes Lactate dehydrogenase LD,
Aspartate Aminotransferase
(AST) and Creatine kinase (CK).
CE 1562, 1563
Coagulation Studies Prothrombin time, activated
partial thromboplastin time and
fibrinogen plus one or more of
the following tests-Bleeding
time, thrombin clotting time,
fibrinogen degradation
products, fibrin monomer,
D-dimer, Factor XIII screening
tests COAG 1527, 1528
Electrolytes Sodium (NA),
Potassium (K),
Chloride (CL) and Bicarbonate
(HCO3). E 1564, 1565
Lipid Studies Cholesterol (CHOL) and
Triglycerides (TRIG), FATS 1560, 1561
Liver Function Tests
Alkaline phosphatase (ALP),
Alanine aminotransferase (ALT),
Aspartate aminotransferase
(AST) ,
Albumin (ALB),
Bilirubin (BIL),
Gamma glutamyl transpeptidase
(GGT) ,
Lactate dehydrogenase (LDH) and
Protein (PROT). LFT 1571, 1572
Syphilis Serology Rapid plasma reagin test (RPR)
or venereal disease research
laboratory test (VDRL) and
Treponema pallidum haemagglutin
test (TPHA) or Fluorescent
Treponemal antibody-absorpotion
test (FTA) STS 2183, 2184
------------------------------------------------------------------------------
-- B. ABBREVIATIONS FOR INDIVIDUAL TESTS The abbreviations are listed
alphabetically within Divisions. The Divisions are: HAEMATOLOGY CHEMICAL
PATHOLOGY MICROBIOLOGY IMMUNOLOGY HISTOPATHOLOGY CYTOPATHOLOGY CYTOGENETICS
INFERTILITY & PREGNANCY TESTS
------------------------------------------------------------------------------
-- Approved Item Name of test in Schedule Abbreviation Numbers
------------------------------------------------------------------------------
-- DIVISION 1 HAEMATOLOGY
Antithrombin III ATH 1531, 1532
Abnormal haemoglobins-spectroscopic
examination of blood AH 1419, 1420
Bleeding Time BT 1521, 1522
Blood coagulation factors-quantitative assays:
Von Willebrands factor antigen VWA 1541, 1542
Von Willebrands factor VWF 1541, 1542
Fletcher Factor FF 1541, 1542
Fitzgerald Factor FGF 1541, 1542
Passovy Factor PF 1541, 1542
Factor II FII 1541, 1542
Factor V FV 1541, 1542
Factor VII FVII 1541, 1542
Factor VIII VIII 1541, 1542
Factor IX FIX 1541, 1542
Factor X FX 1541, 1542
Factor XI FXI 1541, 1542
Factor XII FXII 1541, 1542
Factor XIII FXIII 1541, 1542
Blood Film BF 1170, 1171
Blood Group Antibodies BGA 1417, 1418
Blood Grouping-ABO and RH (D antigen) BG 1187, 1188
Blood Group and blood group antibodies (group and
hold) BGAB 1196, 1197
Blood Group Systems (Duffy, Kell, M&N factors, Rh
phenotypes) BGS 1192, 1193
Bone Marrow Examination-Threphine BMET 1181, 1182
Bone Marrow Examination-Aspirate BMEA 1183, 1184
Coagulation Time CT 1521, 1522
Cold Agglutinins CAG 1419, 1420
Compatibility testing XMAT 1198, 1199
C-reactive protein CRP 1163, 1164
Differential Cell Count DIFF 1170, 1171
Direct Coombs test CMBS 1419, 1420
D-dimer test DD 1521, 1522
Erythrocyte Count RCC 1163, 1164
Erythrocyte Metabolic Enzymes ERYM 1176, 1177
Erythrocyte Sedimentation Rate ESR 1163, 1164
Erythrocyte Haemolysis ERYH 1176, 1177
Euglobulin clot lysis time ECLT 1531, 1532
Fibrinogen Degradation Products FDP 1521, 1522
Fibrin Monomer FM 1521, 1522
Fibrinogen FIB 1521, 1522
Full Blood Examination FBE 1172, 1173
Haemoglobin Estimation HB 1163, 1164
Haemoglobinopathy tests HMGP 1179, 1180
Heparin Cofactor II HRNC 1531, 1532
Heparin estimation HEPR 1539, 1540
Heterophile Antibodies (Infectious Mononucleosis
Test) IM 1419, 1420
Leucocyte Count WCC 1163, 1164
Lupus Anticoagulant LUPA 1531, 1532
Metalbumin detection (Schumm's test) SCHM 1419, 1420
Plasminogen PLAS 1531, 1532
Partial Thromboplastin Time PTT 1521, 1522
Platelet Aggregation PLTG 1535, 1538
Platelet Count PLTC 1163, 1164
Protein C PROC 1531, 1532
Protein S PROS 1531, 1532
Prothrombin Time PT 1521, 1522
Red Cell Porphyrins-qualitative test RCP 1419, 1420
Reticulocyte Count RETC 1163, 1164
Test for Factor XIII deficiency F13D 1521, 1522
Thalassaemia Studies TS 1179, 1180
Thrombin Time TT 1521, 1522
Viscosity of blood or plasma VISC 1163, 1164
DIVISION 2 CHEMICAL PATHOLOGY
Alanine Aminotransferase ALT 1558, 1559
Albumin ALB 1558, 1559
Alcohol (Ethanol) ETOH 1791, 1792
Alkaline Phosphatase ALP 1558, 1559
Alkaline Phosphatase Isoenzymes ALPI 1734, 1735
Amniotic Fluid Examination AFE 1726, 1727
Ammonia NH3 1791, 1792
Amylase AMS 1558, 1559
Angiotensin coverting enzyme ACE 1791, 1792
Aspartate Aminotransferase AST 1558, 1559
Bicarbonate HC03 1558, 1559
Bilirubin (all fractions) BILI 1558, 1559
Bilirubin (Neonatal) BILN 1791, 1792
Blood Gases GAS 1590, 1591
Calcium (total, dialysed or ionized) CA 1558, 1559
Calculus Analysis CALC 1595, 1596
Catecholamines CAT 1959, 1960
Cholinesterase CHSE 1791, 1792
Chloride CL 1558, 1559
Cholesterol CHOL 1558, 1559
Cystine (cysteine) CYST 1791, 1792
C-reactive protein CRP 1558, 1559
Creatine Kinase CK 1558, 1559
Creatine Kinase Isoenzymes CKI 1558, 1559
Creatine Kinase Isoenzymes-quantitative or
qualitative estimation by Electrophoresis CKIE 1734, 1735
Creatinine C 1558, 1559
Cryoglobulins CGLB 1575, 1576
Cryofibrinogen CFIB 1575, 1576
Dexamethazone Suppression test DEXA 2021, 2024
Drug or Chemical Assays-Overdose DRGO 1598, 1599
Drug Assays-Drug abuse treatment programme
including urinary drug screen DRGA 1627, 1628
Drug Assays-Therapeutic:
Antibiotics or antimicrobial chemotherapeutic agents (see under microbiology)
Acetylated Sulphadimidine ASUL 1712, 1713
Amiodarone AMIO 1712, 1713
Amitriptyline AMIT 1712, 1713
Amylobarb AMYL 1712, 1713
Barbitone BARB 1712, 1713
Bromide BRMD 1712, 1713
Butobarb BUTO 1712, 1713
Carbamazepine (Tegretol) CARB 1712, 1713
Chloral Hydrate CHHY 1712, 1713
Chlorazepate CHZP 1712, 1713
Chlorpromazine CHLO 1712, 1713
Chloroquine CLOQ 1712, 1713
Cimetidine CMTD 1712, 1713
Clobazam CLOB 1712, 1713
Clonazepam (rivotril) CLON 1712, 1713
Cyclosporin A CLSA 1712, 1713
Desethyl Amiodarone DEAM 1712, 1713
Desipramine DESI 1712, 1713
Diazepam DIAZ 1712, 1713
Digoxin DIG 1712, 1713
Diphenylhydantion (Dilantin) DIL 1712, 1713
Disopyramide (Rythmodan) DISO 1712, 1713
Dothiepin DOTH 1712, 1713
Doxepin DOXE 1712, 1713
Ethosuximide (Zarontin) ETHO 1712, 1713
Flecainide FLEC 1712, 1713
Hydroxychloriquine HOCQ 1712, 1713
Imipramine IMIP 1712, 1713
Lignocaine LIGN 1712, 1713
Lithium LI 1712, 1713
Methadone MTDN 1712, 1713
Methotrexate MTTA 1712, 1713
Methsuximide MSUX 1712, 1713
Metronidazole MRDZ 1712, 1713
Mexilitine (Mexitil) MEX 1712, 1713
N Acetyl Procainamide NAPC 1712, 1713
N Desalkyl Clobazam NDAC 1712, 1713
N Desalkyl Doxepin NDAD 1712, 1713
Nitrazepam NITR 1712, 1713
Nordothiepin NDIP 1712, 1713
Nortriptyline NORT 1712, 1713
Oxazepam OXAZ 1712, 1713
Paracetamol PARA 1712, 1713
Paraquat PARQ 1712, 1713
Pentabarb PENT 1712, 1713
Phenobarbitone PHBA 1712, 1713
Phensoximide PHEN 1712, 1713
Primidone PRIM 1712, 1713
Procainamide PCAM 1712, 1713
Prominal PROM 1712, 1713
Propranolol PPNO 1712, 1713
Quinalbarb QUIB 1712, 1713
Quinine QNN 1712, 1713
Quinidine QUIN 1712, 1713
Salicylate-Asprin SALI 1712, 1713
Sotalol SALL 1712, 1713
Stellazine STEL 1712, 1713
Sulphadimidine SPDD 1712, 1713
Sulthiame (Ospolot) SUL 1712, 1713
Theophylline THEO 1712, 1713
Thiopentone TOPO 1712, 1713
Thioridazine THIO 1712, 1713
Tocainide TOCN 1712, 1713
Trimipramine TRIM 1712, 1713
Valproate (Epilum) VALP 1712, 1713
Warfarin WFR 1712, 1713
Therapeutic drugs which are not listed above must be written in full
Electrophoresis EPP 1734, 1735
Elements:
Aluminium AL 1871, 1872
Arsenic AS 1871, 1872
Beryllium BE 1871, 1872
Cadmium CD 1871, 1872
Chromium CR 1871, 1872
Copper CU 1871, 1872
Gold AU 1871, 1872
Lead PB 1871, 1872
Manganese MN 1871, 1872
Mercury HG 1871, 1872
Nickel NI 1871, 1872
Selenium SE 1871, 1872
Strontium SR 1871, 1872
Zinc ZN 1791, 1792
Enzyme assays of solid tissue or tissues ENZS 1969, 1970
Faecal Fat FFAT 1963, 1964
Faecal Haemoglobin (chemical test) FBT 1577, 1578
Faecal Porphyrins (qualitative test) FPR 1577, 1578
Faecal Reducing Substances FRS 1577, 1578
Faecal Haemoglobin (immunological test) FBI 1581, 1582
Fructosamine FRUC 1558, 1559
Gamma Glutamyl Transpeptidase GGT 1558, 1559
Globulin GLOB 1558, 1559
Glucose GLUC 1558, 1559
Glucose Tolerance Test GTT 1558, 1559
Glycosylated Haemoglobin (Hb Alc) GHB 2043, 2044
HDL Cholestrol HDLC 2039, 2040
Hormones:
Adrenocorticotrophic hormone ACTH 2021, 2024
Aldosterone ALDS 2021, 2024
Androstenedione ANDR 2021, 2024
C-Peptide CPEP 2021, 2024
Calcitonin CALT 2021, 2024
Cortisol CORT 2021, 2024
Cyclic AMP CAMP 2021, 2024
Dehydroepiandrosterone sulphate DHEA 2021, 2024
Follicular Stimulating Hormone FSH 2021, 2024
Gastrin GAST 2021, 2024
Growth Hormone GH 2021, 2024
Hydroxyprogesterone OHP 2021, 2024
Insulin INS 2021, 2024
Luteinizing Hormone LH 2021, 2024
Oestradiol E2 2021, 2024
Oestriol E3 2021, 2024
Oestrone E1 2021, 2024
Parathyroid Hormone PTH 2021, 2024
Prolactin PROL 2021, 2024
Progesterone PROG 2021, 2024
Renin REN 2021, 2024
Sex Hormone Binding globulin SHBG 2021, 2024
Testosterone TES 2021, 2024
Urine Steroid Fraction or Fractions USF 2021, 2024
Vasoactive Intestinal Peptide VIP 2021, 2024
Hormone Receptor Assay HRA 2037-2038
HIAA (Hydroxyindoleacetic acid) HIAA 1791, 1792
HMMA (Hydroxy Methoxy Mandelic acid previously
known as VMA) HMMA 1959, 1960
HVA (Homovanillic acid) HVA 1959, 1960
Hydroxproline HYDP 1791, 1792
Intestinal disaccharidases INTD 1969, 1970
Iron Studies (Iron, Transferrin and Ferritin) IS 1752, 1753
Lactate LACT 1791, 1792
Lactate Dehydrogenase LDH 1558, 1559
Lactate Dehydrogenase Isoenzymes LDI 1734, 1735
Lecithin/Sphingomyelin Ratio (Amniotic fluid) LS 1726, 1727
Lipase LIP 1558, 1559
Magnesium MG 1558, 1559
MHPG (Methoxy Hydroxy Phenyethylene Glycol) MHPG 1959, 1960
Osmolality, Serum or Urine OSML 1583, 1584
Oxalate OXAL 1791, 1792
PAA (Phenyl Acetic Acid) PAA 1959, 1960
Palmitic acid in amniotic fluid PALM 1726, 1727
pH measurement of body fluids other than urine PH 1575, 1576
Phosphate PHOS 1558, 1559
Porphyrins (quantitative test, one or more
fractions) PR 1959, 1960
Potassium K 1558, 1559
Prostatic Acid Phosphatase (one or more fractions) ACP 1738, 1739
Protein (Total) PROT 1558, 1559
Protein-Quantitative Estim. of Specific Protein:
Alpha feto protein AFP 1738, 1739
Alpha-1 antitrypsin AAT 1738, 1739
Alpha-2 microglobulin AMIC 1738, 1739
Beta-2 microglobulin BMIC 1738, 1739
CA-125 antigen C125 1738, 1739
CA-19.9 antigen CA19 1738, 1739
CA-15.3 antigen CA15 1738, 1739
C-1 esterase inhibitor CEI 1738, 1739
Caeruloplasmin CPLS 1738, 1739
Carcinoembryonic antigen CEA 1738, 1739
Ferritin FERR 1738, 1739
Haptoglobins HGLB 1738, 1739
Microalbumin MALB 1738, 1739
Prostate specific antigen PSA 1738, 1739
Transferrin TRAN 1738, 1739
Pyruvate PVTE 1791, 1792
Red Cell Folate and Serum B12 and if required,
serum folate RCF 1770, 1771
Serum B12 B12 1768, 1769
Serum Folate FOL 1768, 1769
Sodium NA 1558, 1559
Synacthen Stimulation Test SYNS 2021, 2024
Thyroid Function Tests TFT 1983, 1984
Thyrotrophin Releasing Hormone Test TRH 1985, 1986
Triglycerides TRIG 1558, 1559
Urate URAT 1558, 1559
Urea U 1558, 1559
Urine Bilirubin UBIL 1575, 1576
Urine Cystine (Cysteine) UCYS 1575, 1576
Urine Haemoglobin UHB 1575, 1576
Urine Melanin (Melanogen) UML 1575, 1576
Urine Myoglobin UMY 1575, 1576
Urine Porphobilinogen UPG 1575, 1576
Urine Porphyrins (qualitative test) UPR 1575, 1576
Urine Urobilinogen UUB 1575, 1576
Vitamin Quantitative Estimation of Vitamins A, B1,
B2, B3, B6, C or E VIT 1780, 1783
Vitamin D VITD 1786, 1787
Xylose XYL 1791, 1792
DIVISION 3-MICROBIOLOGY Antibiotic and antimicrobial chemotherapeutic
agents, quantitative assay QAA 2235, 2236
Blood Culture BC 2123, 2124
Cultural Examination of Faeces FCS 2117, 2118
Herpes Simplex Virus Investigation by Cultural
Methods HSVC 2139, 2140
Chlamydia Investigation by Cultural Methods CHLC 2139, 2140
Microbial Antibody Testing:
IgG, IgM, IgA, or total antibodies may be tested against various organisms.
These are indicated by placing the letter G, M A and T respectively on the end
of the 3 letter abbreviation
Actinomycetes ACT 2181, 2182
Adenovirus ADE 2181, 2182
Aspergillus ASP 2181, 2182
Avian Precipitins (Bird Fancier's Disease) APP 2181, 2182
Blastomyces BLM 2181, 2182
Bordetella pertussis BOR 2181, 2182
Borrelia Berghoffer BOB 2181, 2182
Brucella BRU 2181, 2182
Campylobacter Jejuni CAM 2181, 2182
Candida CAN 2181, 2182
Chlamydia CHL 2181, 2182
Coccidioides CCC 2181, 2182
Coxsackie B1-6 COX 2181, 2182
Cryptococcus CRY 2181, 2182
Cytomegalovirus CMV 2181, 2182
Cytomegalovirus serology in pregnancy CMVP 2145, 2146
Dengue DEN 2181, 2182
Diphtheria DIP 2181, 2182
Echinococcus ECC 2181, 2182
Echo-coxsackie group ECH 2181, 2182
Entamoeba Histolytica AMO 2181, 2182
Epstein Barr Virus EBV 2181, 2182
Fluorescent Treponemal antibody-absorption test
(FTA-ABS) FTA 2181, 2182
Haemophilus HUS 2181, 2182
Hepatitis delta antibody-Anti-delta HDA 2181, 2182
Histoplasma HIP 2181, 2182
Hydatid HYD 2181, 2182
Influenza A FLA 2181, 2182
Influenza B FLB 2181, 2182
Legionella pneumophila-Serogroup 1 LP1 2181, 2182
Legionella pneumophila-Serogroup 2 LP2 2181, 2182
Leishmaniasis LE1 2181, 2182
Leptospira LEP 2181, 2182
Listeria LIS 2181, 2182
Measles MEA 2181, 2182
Micropolyspora faeni MIC 2181, 2182
Mumps MUM 2181, 2182
Murray Valley Encephalitis MVE 2181, 2182
Mycoplasma pneumoniae MYC 2181, 2182
Neisseria gonorrhoea GON 2181, 2182
Newcastle Disease NCD 2181, 2182
Parainfluenza 1 PF1 2181, 2182
Parainfluenza 2 PF2 2181, 2182
Parainfluenza 3 PF3 2181, 2182
Paratyphi PTY 2181, 2182
Pertussis PER 2181, 2182
Pneumococcus PCC 2181, 2182
Poliomyelitis PLO 2181, 2182
Proteus OX 19 POX 2181, 2182
Proteus OXK POK 2181, 2182
Q fever QFF 2181, 2182
Rapid Plasma Reagin test RPR 2181, 2182
Respiratory Syncytial Virus RSV 2181, 2182
Ross River Virus RRV 2181, 2182
Rubella RUB 2145, 2146
Rubella Serology in Pregnancy RUBP 2181, 2182
Salmonella typhi (H) SAH 2181, 2182
Salmonella typhi (O) SAO 2181, 2182
Schistosoma STO 2181, 2182
Streptococcal Serology-Anti-D-NASE B titre ADNB 2181, 2182
Streptococcal Serology-Anti-Streptolysin O ASOT 2181, 2182
Tetanus TET 2181, 2182
Thermoactinomyces vulgaris THE 2181, 2182
Thermopolyspora TPS 2181, 2181
Toxocara TOC 2181, 2182
Toxoplasma TOX 2181, 2182
Toxoplasma serology in pregnancy TOXP 2145, 2146
Treponema pallidum haemagglutin test TPHA 2181, 2182
Trichonosis TOS 2181, 2182
Typhus, Weil-Felix TYP 2181, 2182
Varicella zoster VCZ 2181, 2182
Venereal Disease Research Laboratory (VDRL) VDRL 2181, 2182
Yersinia enterocolytica YER 2181, 2182
Microbial antibody tests which are not listed above must be written in full
Hepatitis Serology
Hepatitis Serology in acute hepatitis HEP 2229, 2230
Hepatitis B Serology in follow-up of proven
Hepatitis B HEPB 2231, 2232
Hepatitis B surface Antigen HBsAg HBSA 2221, 2222
Hepatitis B Serology to define immune status HEPI 2223, 2224
Microbial Antigen Testing:
Chlamydia CHLY 2133, 2134
Herpes Simplex Virus HSV 2133, 2134
CSF antigens-Haemophilus influenzae, Streptococcus pneumoniae, Neisseria
meningitidis, Group B
streptococcus CSFA 2129, 2130
Cryptococcal antigen CRYN 2129, 2130
RSV-respiratory Syncytial virus RSVN 2129, 2130
Varicella zoster VCZN 2129, 2130
Microscopic examination of material other than
blood M 2083, 2084
Microscopic examination of faeces for parasites OCP 2085, 2086
Microscopy and culture of material from Nose,
Throat, Eye or Ear MCS1 2087, 2088
Microscopy and culture of material from Skin, Super-ficial sites, urethra,
vagina, cervix, sputum
or Rectum MCS2 2089, 2090
Microscopy and culture of material from post Operative Wounds, Aspirations of
Body Cavities, Synovial fluid, CSF and operative or biopsy
specimens MCS3 2098, 2099
Microscopy and culture of Sputum for Mycobacteria AFB 2119, 2020
Urine microscopy, culture, identification and
sensitivity UMCS 2127, 2128
DIVISION 4-IMMUNOLOGY
Specific IgG or IgE antibodies ALLG 2259, 2260
Antibodies to Tissue Antigens:
Acetylcholine Receptor ARA 2271, 2274
Adrenal cell ADR 2271, 2274
Cardiolipin ACL 2271, 2274
Centromere ACA 2271, 2274
Gliad in IgA GLIA 2271, 2274
Gastric parietal cell PCA 2271, 2274
Glomerular basement membrane GBA 2271, 2274
Insulin Receptor Antibodies INSA 2271, 2274
Intercellular cement substance of skin ICCS 2271, 2274
Jo-1 JO1 2271, 2274
Keratin KERA 2271, 2274
Liver/Kidney microsomes LKA 2271, 2274
Mitochondria MA 2271, 2274
Parathyroid PTHA 2271, 2274
PM-1 PM1 2271, 2274
Reticulin RCA 2271, 2274
Rheumatoid Factor (all tests including Latex test)
RF 2281, 2282
SCL 70 SCL 2271, 2274
Skeletal Muscle SLA 2271, 2274
Skin basement membrane SKA 2271, 2274
Smooth Muscle SMA 2271, 2274
Thyroglobulin TGA 2271, 2274
Thyroid Microsomal TMA 2271, 2274
TSH Receptor Antibody test TSHA 2271, 2274
Tissue antigens which are not listed above must be written in full
Antibodies to Nuclear Antigens-detection ANA 2261, 2262
Antibodies to Nuclear Antigens-quantitation and
measurement of DNA binding if positive ANA ANAP 2263, 2266
Antibodies to Extractable Nuclear
Antigens-detection ENA 2267, 2268
Antibodies to Extractable Nuclear Antigens-characterization of antibodies if
positive
ENA ENAP 2269, 2270
Complement total, C3 or C4 COM 2289, 2290
Other complements must be specified
HLA Typing, comprising A, B, C and DR phenotypes HLA 2321, 2322
HLA Typing, one or more antigens HLAN 2323, 2324
Immunoglobulins G, A, M or D IG 2245, 2246
Immunoglobulin G, sub classes 1-4 SIGG 2255, 2256
Immunoglobulins E IGE 2261, 2262
Leucocyte Fractionation LF 2313, 2314
Leucocyte functional Tests LFF 2315, 2316
Leucocyte Surface Markers to assess Lymphoid
populations LSML 2317, 2318
Leucocyte Surface Markers in investigation of
probable haematological malignancy LSMH 2319, 2320
Mantoux Test MANT 2325, 2326
Paraprotein Investigation by Immuno-electrophoresis
or immunofixation PPRO 2239, 2240
Paraprotein Investigation on concurrently collected
serum and urine PPSU 2241, 2242
DIVISION 5 HISTOPATHOLOGY
Electron microscopy and biopsy material EM 2333, 2337
Histopathology of biopsy material HIST 2327, 2328
Immediate frozen section diagnosis of biopsy
material FS 2329, 2330
Immunohistochemical investigation of biopsy
material IHIS 2331, 2332
DIVISION 6 CYTOPATHOLOGY
Cytology from cervix or vagina CXCY 2338, 2339
Cytology from skin, nipple discharge, lip, mouth,
nose or anus SMCY 2340, 2341
Cytology from body fluids, urine or washing BFCY 2340, 2341
Cytology from body fluids, aspiration of solid
tissues FNCY 2350, 2351
Cytology from fine needle aspiration of solid
tissues-aspiration or attendance by pathologist FNCP 2355, 2356
DIVISION 7 CYTOGENETICS
Chromosome studies CS 2360, 2361
Chromosome studies of blood CSB 2363, 2364
Chromosome identification by banding techniques CSI 2365, 2366
DIVISION 8 INFERTILITY AND PREGNANCY TESTS
Semen examination for spermatozoa SES 2370, 2371
Huhner's test HT 2370, 2371
Semen examination SEE 2372, 2373
Sperm antibodies SAB 2377, 2378
Sperm penetrating ability SPA 2377, 2378
Chorionic gonadotrophin for pregnancy diagnosis HCG 2379, 2380
Chorionic gonadotrophin for diagnosis of specified
conditions HCGD 2384, 2385
AustLII: Copyright Policy
| Disclaimers
| Privacy Policy
| Feedback